arrow
M

Merve Keskinkılıç

izmir democracy university
H指数:9
被引数:257

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

三阴性乳腺癌新辅助化疗患者的CPS-EG评分的预后意义

Cancers
IF4.4
2026-08-180
OA
Diabetes Increases Immunotherapy-Related Toxicity but Not Efficacy in Metastatic Non-Small Cell Lung Cancer: A Multicenter Retrospective Study

糖尿病增加转移性非小细胞肺癌免疫治疗相关毒性但未影响疗效:一项多中心回顾性研究

2026-08-160
OAAI
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study (vol 14, 23556, 2024)
2025-03-180
OAAI
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
2024-12-300
OAAI
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

细胞周期蛋白依赖性激酶抑制剂后依维莫司加激素治疗的疗效; 现实生活经验,TOG研究

2024-08-090
PRE
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study

低HER2表达对接受CDK4/6抑制剂联合内分泌治疗的转移性激素受体阳性乳腺癌患者治疗结局的影响: 一项多中心回顾性研究

BREAST
IF7.9
2023-08-019
OAAI
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

瑞博西尼或帕博西尼联合来曲唑治疗激素受体阳性/HER2-negative转移性乳腺癌的疗效

2023-05-0310
PRE
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者中后续治疗的疗效 (第23卷,136,2023)

2023-02-272
OAAI
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者的后续治疗效果

2023-02-1016
OAAI
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
BREAST
IF7.9
2022-12-0112
OAAI
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

晚期ALK阳性非小细胞肺癌患者一线阿来替尼治疗疗效和安全性的真实数据: 土耳其肿瘤学组研究

2022-06-231
PRE